# Microbot Medical Inc.: overview MBOT · Nasdaq · CIK 883975 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/mbot.md) · [Financials](/companies/mbot/financials.md) · [Filings](/companies/mbot/filings.md) · [Insiders](/companies/mbot/insiders.md) Latest reported revenue: [$241.0k](/filings/0001493152-26-037009.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 11, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-26-037009). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | [105](/filings/0001493152-26-022792.md) | [241](/filings/0001493152-26-037009.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | [1.9%](/filings/0001493152-26-022792.md) | [(266.8%)](/filings/0001493152-26-037009.md) | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | [(4114.3%)](/filings/0001493152-26-022792.md) | [(2567.6%)](/filings/0001493152-26-037009.md) | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | [(3496.2%)](/filings/0001493152-26-037009.md) | [(2334.9%)](/filings/0001493152-26-037009.md) | | Diluted EPS | $ per share | [(0.20)](/filings/0001493152-25-021929.md) | not reported | [(0.08)](/filings/0001493152-26-022792.md) | [(0.10)](/filings/0001493152-26-037009.md) | [(0.07)](/filings/0001493152-25-021929.md) | not reported | [(0.05)](/filings/0001493152-26-022792.md) | [(0.08)](/filings/0001493152-26-037009.md) | | Free cash flow | $k | [(2,759) d](/filings/0001493152-25-021929.md) | [(1,698) d](/filings/0001493152-26-012935.md) | [(2,887)](/filings/0001493152-26-022792.md) | [(2,582) d](/filings/0001493152-26-037009.md) | [(3,854) d](/filings/0001493152-25-021929.md) | [(3,783) d](/filings/0001493152-26-012935.md) | [(5,161)](/filings/0001493152-26-022792.md) | [(5,131) d](/filings/0001493152-26-037009.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.59)](/filings/0001493152-22-008344.md) | [(1.81)](/filings/0001493152-24-011521.md) | [(1.05)](/filings/0001641172-25-000614.md) | [(0.73)](/filings/0001493152-26-012935.md) | [(0.29)](/filings/0001493152-26-012935.md) | | Free cash flow | $m | [(9.4)](/filings/0001493152-23-010223.md) | [(11.6)](/filings/0001493152-24-011521.md) | [(8.6)](/filings/0001641172-25-000614.md) | [(8.9)](/filings/0001493152-26-012935.md) | [(13.1)](/filings/0001493152-26-012935.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/mbot/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $5.7m | 2,906,810 | | Reduced −2,715 | | [Mitsubishi UFJ Asset Management Co., Ltd.](/funds/1466546.md) | 2026-06-30 | $2.5m | 1,268,453 | | New +1,268,453 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.8m | 902,411 | | Added +45,013 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $1.6m | 836,271 | | Added +75,440 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $1.6m | 806,847 | | Reduced −10,098 | | [DNB Asset Management AS](/funds/1456670.md) | 2026-06-30 | $1.3m | 677,498 | | Unchanged | | [STIFEL FINANCIAL CORP](/funds/720672.md) | 2026-06-30 | $1.2m | 589,924 | | Added +16,849 | | [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $1.1m | 541,963 | | Added +60,918 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $1.0m | 525,827 | | Reduced −398,480 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $840.5k | 431,033 | | Added +30,808 | ## Recent filings [All 1,139 filings](/companies/mbot/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-23 | 08:30 ET | [8-K](/filings/0001493152-26-048182.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-048182 | | 2026-10-20 | 08:30 ET | [8-K](/filings/0001493152-26-047702.md) | 5.08 Item not in the standard list; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-047702 | | 2026-10-06 | 08:30 ET | [8-K](/filings/0001493152-26-045866.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-045866 | | 2026-09-28 | 06:24 ET | [8-K](/filings/0001493152-26-044429.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-044429 | | 2026-08-11 | 10:28 ET | [8-K](/filings/0001493152-26-037031.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-037031 | | 2026-08-11 | 09:15 ET | [10-Q](/filings/0001493152-26-037009.md) | Quarterly report, period 2026-06-30 | 0001493152-26-037009 | | 2026-08-07 | 16:30 ET | [8-K](/filings/0001493152-26-036600.md) | 1.01 Entry into a material agreement; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001493152-26-036600 | | 2026-07-21 | 08:30 ET | [8-K](/filings/0001493152-26-034014.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-034014 | | 2026-07-07 | 08:30 ET | [8-K](/filings/0001493152-26-032260.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-032260 | | 2026-06-30 | 08:30 ET | [8-K](/filings/0001493152-26-031205.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-031205 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-012935.md), filed Mar 26, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/03fa0fac-00a2-4fb1-a7f2-1da070be86ab) ## About the filer - CIK: 883975 - Tickers: MBOT - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 08:31 ET. No prices; not investment advice.